Merck’s Keytruda wins a double-header with new FDA approval in head-and-neck cancer

Merck & Co.’s Keytruda saw its fortunes rise significantly Friday, and not just because its Bristol-Myers Squibb rival failed a key lung cancer study. Keytruda picked up a spanking-new FDA approval, too.

Source: Merck’s Keytruda wins a double-header with new FDA approval in head-and-neck cancer

Published by

marypathigleymedi

Newport Beach resident with interests in clinical medicine, social media, gardening, dog therapy training, spiritual growth, volunteering in the community. Shetland Sheepdog enthusiast

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s